

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study.

For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-----|-----------|
| n/a | Confirmed |
|-----|-----------|
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
 - A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
 - The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
 - A description of all covariates tested
 - A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
 -
 - A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
 - For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
 - For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
 - For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
 - Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
- Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

Software and code

Policy information about [availability of computer code](#)

- | | |
|-----------------|--|
| Data collection | <input type="text" value="To collect the data in this study, the following softwares were used:"/> |
| Data analysis | <input checked="" type="checkbox"/> The R-package MACP that was used to analyze the data was released as an open-source code under the MIT license that is available on GitHub |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The raw co-fractionation data from this work is available at ProteomeXchange with the identifier PXD039444, in accordance with the data sharing policy.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	<input type="text" value="We did not perform any sex- and gender-based analyses as they are not considered in the study design, and is not relevant to"/>
Reporting on race, ethnicity, or other socially relevant groupings	<input type="text" value="Not applicable"/>
Population characteristics	<input type="text" value="Not applicable"/>
Recruitment	<input type="text" value="Not applicable"/>
Ethics oversight	<input type="text" value="Not applicable"/>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<input type="text" value="Altogether 192 SEC-HPLC and 168 IEX-HPLC-based separations were collected in replicate runs from the mitochondrial extracts of adult whole"/>
Data exclusions	<input type="text" value="No data were excluded from the analyses."/>
Replication	<input type="text" value="We show that the average correlation of peptide counts detected between replicate fractionation experiments were highly reproducible, and"/>
Randomization	<input type="text" value="In Fig. 6g, correlated co-fitness profiles of human orthologs of interacting mouse mt proteins was compared to random pairs based on co-"/>
Blinding	<input type="text" value="There is no blinding employed with respect to the sample selection due to the use of objective means of quantification. Nevertheless, the"/>

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<input type="text"/>
Research sample	<input type="text"/>
Sampling strategy	<input type="text"/>
Data collection	<input type="text"/>
Timing	<input type="text"/>
Data exclusions	<input type="text"/>
Non-participation	<input type="text"/>
Randomization	<input type="text"/>

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<input type="text"/>
Research sample	<input type="text"/>
Sampling strategy	<input type="text"/>
Data collection	<input type="text"/>
Timing and spatial scale	<input type="text"/>
Data exclusions	<input type="text"/>
Reproducibility	<input type="text"/>
Randomization	<input type="text"/>

Blinding

Did the study involve field work? Yes No

Field work, collection and transport

Field conditions

Location

Access & import/export

Disturbance

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- n/a | Involved in the study
- Antibodies
 - Eukaryotic cell lines
 - Palaeontology and archaeology
 - Animals and other organisms
 - Clinical data
 - Dual use research of concern
 - Plants

Methods

- n/a | Involved in the study
- ChIP-seq
 - Flow cytometry
 - MRI-based neuroimaging

Antibodies

Antibodies used Antibodies used in immunoblotting experiments

Validation The antibodies validated by the manufacturer are listed below:

Eukaryotic cell lines

Policy information about [cell lines](#) and [Sex and Gender in Research](#)

Cell line source(s) NTERA-2 cl.D1 undifferentiated human pluripotent embryonal carcinoma stem cells was obtained from ATCC (Cat# CRL-1973;

Authentication Authentication and quality-control tests on the NTERA-2 cl.D1 cell line was comprehensively performed by ATCC.

Mycoplasma contamination Cell lines used for research purpose were regularly checked, and they were free from mycoplasma contamination.

Commonly misidentified lines (See [ICLAC](#) register) Not applicable

Palaeontology and Archaeology

Specimen provenance

Specimen deposition

Dating methods

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	Brain was excised from the euthanized 1 year-old female C57BL/6J adult mice.
Wild animals	Study did not involve wild animals.
Reporting on sex	Since sex was not considered in the study design, the current results cannot be applied to only one type of sex.
Field-collected samples	Study did not involve samples collected from the field.
Ethics oversight	The use of mouse brain or human fibroblast samples as part of this protocol that was approved by the University of Regina President's

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	
Study protocol	
Data collection	
Outcomes	

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

- | | |
|-----------------------|----------------------------|
| No | Yes |
| <input type="radio"/> | <input type="radio"/> |
| | Public health |
| <input type="radio"/> | <input type="radio"/> |
| | National security |
| <input type="radio"/> | <input type="radio"/> |
| | Crops and/or livestock |
| <input type="radio"/> | <input type="radio"/> |
| | Ecosystems |
| <input type="radio"/> | <input type="radio"/> |
| | Any other significant area |

Experiments of concern

Does the work involve any of these experiments of concern:

- | | |
|-----------------------|---|
| No | Yes |
| <input type="radio"/> | <input type="radio"/> |
| | Demonstrate how to render a vaccine ineffective |
| <input type="radio"/> | <input type="radio"/> |
| | Confer resistance to therapeutically useful antibiotics or antiviral agents |
| <input type="radio"/> | <input type="radio"/> |
| | Enhance the virulence of a pathogen or render a nonpathogen virulent |
| <input type="radio"/> | <input type="radio"/> |
| | Increase transmissibility of a pathogen |
| <input type="radio"/> | <input type="radio"/> |
| | Alter the host range of a pathogen |
| <input type="radio"/> | <input type="radio"/> |
| | Enable evasion of diagnostic/detection modalities |
| <input type="radio"/> | <input type="radio"/> |
| | Enable the weaponization of a biological agent or toxin |
| <input type="radio"/> | <input type="radio"/> |
| | Any other potentially harmful combination of experiments and agents |

Plants

Seed stocks	
Novel plant genotypes	
Authentication	

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication

Files in database submission

Genome browser session

(e.g. [UCSC](#))

Methodology

Replicates

Sequencing depth

Antibodies

Peak calling parameters

Data quality

Software

Flow Cytometry

Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Instrument

Software

Cell population abundance

Gating strategy

Detach iPSC-derived motor neurons using StemPro Accutase in the incubator at 37 °C and 5% CO2 for 5 min, transfer the

Beckman Coulter MoFlo XDP cell sorter

Kaluza Analysis Software was used to collect and analyze the flow cytometry data.

The quality (or purity) of the iPSC-derived motor neurons from healthy subject was analyzed by MoFlo XDP cell sorter for 5 min

Single neurons were gated using forward scatter vs. side scatter (FSC/SSC), with signal being detected in the APC channel. Since

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type

Design specifications

Behavioral performance measures

Acquisition

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI

Used

Not used

Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis: Whole brain ROI-based Both

Statistic type for inference

(See [Eklund et al. 2016](#))

Correction

Models & analysis

n/a Involved in the study

Functional and/or effective connectivity

Graph analysis

Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis



